Cipla gets US regulatory nod for generic Epzicom tablets

Global pharmaceutical company Cipla on Tuesday announced that it has received final approval of the US Food and Drug Administration (USFDA) for the generic version of Epzicom tablets -- for the treatment of HIV-1 infection.

"Abacavir and Lamivudine Tablets USP, 600 mg/300 mg, are AB-rated generic equivalents to the reference listed drug (RLD), Epzicom Tablets, 600 mg/300 mg of ViiV Healthcare Company and are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection," the company said in a statement.

"The product will cater to the US market and will be commercially available shortly," it added.

According to IMS Health -- the American firm that provides information, services and technology for the healthcare industry -- Epzicom tablets had US sales of approximately $346.3 million for the 12-month period ending February.

--IANS

ppg/in/dg